# Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated

> **NCT01529749** · PHASE4 · COMPLETED · sponsor: **Felipe Garcia** · enrollment: 48 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** EFV/FTC/TDF + Losartan
- **DRUG:** EFV/FTC/TDF
- **DRUG:** FTC/TDF + MK-0518
- **DRUG:** FTC/TDF+MK-0518+Losartan

## Key facts

- **NCT ID:** NCT01529749
- **Lead sponsor:** Felipe Garcia
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2012-03
- **Final completion:** 2016-02
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2019-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01529749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01529749, "Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01529749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*